Bli medlem
Bli medlem

Du är här

2019-07-09

Karolinska Development AB (publ): Karolinska Development's portfolio company Dilafor initiates Phase 2b clinical trial wit...

STOCKHOLM ? July 9, 2019. Karolinska Development?s portfolio company
Dilafor AB, a drug development company focusing on the development of
tafoxiparin for obstetric indications, has enrolled the first subject in
its Phase 2b study with tafoxiparin in pregnant women planned for labor
induction.

About a quarter of all pregnant women are subject to labor induction. More
than half of these inductions fail, which leads to protracted labor that
entail an increased risk of complications for both mother and child. In a
previous phase 2a study, subcutaneous administration of Dilafor?s drug
candidate tafoxiparin has shown a significant positive effect with a
shortened time to delivery and an enhanced ripening of the cervix in
patients induced into labor.

Dilafor has now enrolled the first subject in a phase 2b study to
investigate in a larger group whether treatment with subcutaneously
administered tafoxiparin can soften the cervix and improve the outcome of
labor induction, and thereby shortening the time to delivery.

The Phase 2b study is a multi-center, double blind, placebo-controlled
proof of concept study in term-pregnant first-time mothers with an unripe
cervix that are planned for labor induction. The pregnant women will be
randomized to either subcutaneous injection of tafoxiparin or placebo once
daily up to one week prior to scheduled labor induction. The treatment is
then followed by induction according to clinical practice, which is usually
balloon catheter or hormonal treatment. The target is to enroll 170
pregnant women in the study that is planned to be performed at delivery
clinics in two countries in Europe. Sweden is the first country to be
included. 

?There is a huge unmet medical need within the obstetric field, and
Dilafor?s tafoxiparin has the potential to become a completely new
treatment option for pregnant women that have high risk of fetal and
maternal complications. That the first patient now is enrolled in the Phase
2b study is an encouraging step in the development of tafoxiparin",
comments Viktor Drvota, CEO of Karolinska Development.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life
sciences investment company. The company focuses on identifying
breakthrough medical innovations in the Nordic region that are developed by
entrepreneurs and leadership teams. The Company invests in the creation and
growth of companies that

advance these assets into commercial products that are designed to make a
difference to patients' lives while providing an attractive return on
investment to shareholders.

Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research
institutes in the Nordic region. The Company aims to build companies around
scientists who are leaders in their fields, supported by experienced
management teams and advisers, and co-funded by specialist international
investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies
targeting opportunities in innovative treatment for life-threatening or
serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals
with a proven track record as company builders and with access to a strong
global network.

For more information, please visit www.karolinskadevelopment.com

Bilaga

* KD Press release Dilafor Phase 2b initiated July 19

Författare Hugin Nyheter

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.